PRESS RELEASE published on 06/13/2025 at 07:30, 9 months 22 days ago Informations privilégiées / Autres communiqués MaaT Pharma présente des données actualisées positives pour Xervyteg® lors du Congrès de l’EHA confirmant une forte efficacité observée dans l’étude pivotale ARES dans la maladie aiguë du greffon contre l’hôte Thérapie MaaT Pharma AGvH Xervyteg EHA
BRIEF published on 05/12/2025 at 07:35, 10 months 24 days ago Données prometteuses pour MaaT033 dans la SLA Microbiome Sclérose Latérale Amyotrophique MaaT033 Sécurité Et Tolérabilité Essai Clinique Phase 1b
BRIEF published on 05/12/2025 at 07:35, 10 months 24 days ago Promising data for MaaT033 in ALS Microbiome Amyotrophic Lateral Sclerosis MaaT033 Safety And Tolerability Phase 1b Clinical Trial
PRESS RELEASE published on 05/12/2025 at 07:30, 10 months 24 days ago Informations privilégiées / Autres communiqués MaaT Pharma annonce des données finales prometteuses pour son essai de Phase 1b évaluant MaaT033 dans la Sclérose Latérale Amyotrophique (SLA). Résultats encourageants et implications thérapeutiques importantes Microbiome Ecosystem Therapies MaaT Pharma Sclérose Latérale Amyotrophique Phase 1b Modulation Du Microbiote
BRIEF published on 04/08/2025 at 07:35, 11 months 27 days ago MaaT Pharma Announces Positive Interim Safety Results for MaaT033 Phase 2B Trial MaaT Pharma MaaT033 Allo-HSCT DSM Safety
BRIEF published on 04/08/2025 at 07:35, 11 months 27 days ago MaaT Pharma annonce des résultats intermédiaires positifs concernant l'innocuité du MaaT033 MaaT Pharma Essai De Phase 2b MaaT033 Allo-GCSH Sécurité DSM
PRESS RELEASE published on 04/08/2025 at 07:30, 11 months 27 days ago Inside Information / Other news releases MaaT Pharma announces positive safety interim analysis from DSMB for Phase 2b trial evaluating MaaT033 for patients receiving Allo-HSCT, demonstrating favorable safety profile and tolerability Phase 2B Trial MaaT Pharma Safety Analysis MaaT033 Allo-HSCT
PRESS RELEASE published on 04/08/2025 at 07:30, 11 months 27 days ago Informations privilégiées / Autres communiqués MaaT Pharma annonce résultat positif analyse intermédiaire sécurité essai clinique Phase 2b MaaT033 allo-GCSH. DSMB recommande poursuite essai sans modification Sécurité DSMB MaaT Pharma Analyse Intermédiaire Allo-GCSH
BRIEF published on 04/07/2025 at 07:35, 11 months 28 days ago MaaT Pharma : Nouvelle couverture par H.C. Wainwright & Co Cancer Cotation Euronext Microbiome Ecosystem Therapies MaaT Pharma H.C. Wainwright & Co
BRIEF published on 04/07/2025 at 07:35, 11 months 28 days ago MaaT Pharma: New cover by HC Wainwright & Co Cancer Euronext Listing Microbiome Ecosystem Therapies MaaT Pharma HC Wainwright & Co
Published on 04/02/2026 at 22:00, 3 days 7 hours ago Star Copper Announces Closing of Charity Flow-Through Unit Private Placement
Published on 04/02/2026 at 18:32, 3 days 11 hours ago Datavault AI CEO Nathaniel Bradley to Present DataValue(R), DataScore(R), and Information Data Exchange(R) Technologies at XRP Tokyo 2026
Published on 04/02/2026 at 15:00, 3 days 14 hours ago Jaguar Health Family Company Napo Pharmaceuticals Co-Sponsoring Pediatric Gastroenterology Conference: Elite Ped-GI Congress
Published on 04/02/2026 at 14:40, 3 days 14 hours ago Northfield Capital Completes Acquisition Of Additional Interest In Juno Corp. And Announces Issuance Of Class B Multiple Voting Shares
Published on 04/02/2026 at 14:30, 3 days 15 hours ago Worksport Announces COR(TM) Portable Energy System Is Now Fully Certified, Including Key UL and CSA Approvals, for North American Retail and Commercial Distribution
Published on 04/04/2026 at 10:07, 1 day 19 hours ago Heidelberg Pharma to Present Data from its ADC Technology Platform at AACR Annual Meeting 2026
Published on 04/04/2026 at 02:05, 2 days 3 hours ago Blokees made its debut at 2026 Thailand Toy Expo, exhibiting multiple products
Published on 04/03/2026 at 18:00, 2 days 11 hours ago IEVA GROUP: IMPLEMENTATION OF A LIQUIDITY AGREEMENT WITH CREDIT INDUSTRIEL ET COMMERCIAL
Published on 04/03/2026 at 18:00, 2 days 11 hours ago IEVA GROUP: MISE EN OEUVRE D’UN CONTRAT DE LIQUIDITE AVEC LE CREDIT INDUSTRIEL ET COMMERCIAL
Published on 04/03/2026 at 17:45, 2 days 11 hours ago Atbash Launches on Chromia to Enable Verifiable, User-Controlled AI Systems
Published on 04/03/2026 at 18:46, 2 days 10 hours ago Disclosure of Share Capital and Voting Rights as of March 31, 2026
Published on 04/03/2026 at 18:46, 2 days 10 hours ago Déclaration du nombre d’actions et droits de vote au 31 mars 2026
Published on 04/03/2026 at 18:01, 2 days 11 hours ago ALTAREIT : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 04/03/2026 at 18:00, 2 days 11 hours ago ALTAREA : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 04/03/2026 at 18:00, 2 days 11 hours ago LANSON-BCC : Déclaration du nombre total des droits de vote et du nombre d’actions au 31 mars 2026
